Press Releases Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 12:45:08 17/07/2025 BST			5-day change	1st Jan Change
12.53 ^EUR	+3.21%		+8.29%	+37.08%

07-16	European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	MT
07-16	Grifols to build plant in Spain to double its plasma fractionation capacity	RE

Press Releases

Grifols S A : will build new manufacturing site in Spain to double its plasma fractionation capacity in Europe	07-16	PU
Grifols S A : ’ positive fibrinogen phase 3 trial results published in The Lancet’s eClinicalMedicine	06-19	PU
Grifols successfully completes Biotest delisting	06-11	AQ
Information on the resolutions approved at the General Shareholders' Meeting of June 5, 2005	06-05	AQ
Grifols S A : receives FDA clearance of IND application for Phase 2 trial of immunoglobulin drops for dry eye disease	05-21	PU
Grifols S A : ’ Alternative Performance Measures (57e6e978 a029 8791 3e73 cb3b16169b78t1747143574382)	05-13	PU
Grifols S A : Conference call transcript (ac59a972 e0a1 3edb df9f 8e7db542ef78t1747143133113)	05-13	PU
Grifols S A : ’ Alternative Performance Measures (57e6e978 a029 8791 3e73 cb3b16169b78t1747067122469)	05-12	PU
Grifols S A : Presentation (1576da7a 3634 411f bba0 5a497574d076t1747065297835)	05-12	PU
Grifols S A : Press Release (36cc6c80 3320 44a2 8fc9 198cdf7b8938t1747065299614)	05-12	PU
Grifols Q1 2025 Financial Results	05-12	AQ
Grifols S A : delivers strong results across the board, increasing revenues by 7.4%, Adj EBITDA by 14.2% and improving free cash flow by EUR 209m	05-12	PU
Grifols S A : delivers strong results across the board, increasing revenues by 7.4%, Adj EBITDA by 14.2% and improving free cash flow by EUR 209m May 12 2025	05-12	PU
Grifols S A : has received today approval from the German federal financial supervisory authority ("BaFin"), to publish the offer document submitted by its fully owned subsidiary Biotest Holdings GmbH	05-06	PU
Grifols has received today approval from the German federal financial supervisory authority ("BaFin"), to publish the offer document submitted by its fully owned subsidiary Grifols Biotest Holdings GmbH	05-06	AQ
Ordinary General Shareholders' Meeting	05-02	AQ
Grifols S A : partners with IBL International to develop advanced biomarker panels for unique clinical diagnostics platform	04-08	PU
Grifols S A : appoints Montse Ribas as Chief Communications and Reputation Officer to strengthen the company's global reputation	04-03	PU
Board of Directors Clarifies no knowledge of restarted discussions on potential offer from Brookfield	04-02	AQ
Grifols has approved that its fully owned subsidiary Grifols Biotest Holdings GmbH, to make a public delisting purchase offer to the shareholders of Biotest AG	03-31	AQ
Grifols S A : and Inpeco joining forces to deliver transfusion medicine ‘lab of the future’	03-20	PU
Grifols S A : Phase 2/3 trial shows positive impact of immunoglobulin therapy on post-polio patients	03-13	PU
Grifols Responds to Misleading Media Report	03-10	AQ
Grifols S A : ’ Alternative Performance Measures (b02f1fed 3ef6 7509 6832 6f58c733b65bt1741594463720)	03-10	PU
Grifols S A : Conference call transcript (e5d630f2 399c cb70 78b3 2819ba648a9at1741187817117)	03-05	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GRIFOLS : Governance and operational improvements are worthy of notice

May 27, 2025 at 01:20 pm

Gotham City sets its sights on Grifols

January 09, 2024 at 03:09 pm